相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Efficacy and safety of low-dose IL-2 in the treatment of systemic lupus erythematosus: a randomised, double-blind, placebo-controlled trial
Jing He et al.
ANNALS OF THE RHEUMATIC DISEASES (2020)
Persistence of adoptively transferred T cells with a kinetically engineered IL-2 receptor agonist
Giulia Parisi et al.
NATURE COMMUNICATIONS (2020)
Bempegaldesleukin selectively depletes intratumoral Tregs and potentiates T cell-mediated cancer therapy
Meenu Sharma et al.
NATURE COMMUNICATIONS (2020)
Long-term follow up of lifileucel (LN-144) cryopreserved autologous tumor infiltrating lymphocyte therapy in patients with advanced melanoma progressed on multiple prior therapies.
Amod Sarnaik et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Bempegaldesleukin (NKTR-214) plus Nivolumab in Patients with Advanced Solid Tumors: Phase I Dose-Escalation Study of Safety, Efficacy, and Immune Activation (PIVOT-02)
Adi Diab et al.
CANCER DISCOVERY (2020)
Overcoming Genetically Based Resistance Mechanisms to PD-1 Blockade
Davis Y. Torrejon et al.
CANCER DISCOVERY (2020)
ALKS 4230: a novel engineered IL-2 fusion protein with an improved cellular selectivity profile for cancer immunotherapy
Jared E. Lopes et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
Stereotactic ablative body radiotherapy (SABR) combined with immunotherapy (L19-IL2) versus standard of care in stage IV NSCLC patients, ImmunoSABR: a multicentre, randomised controlled open-label phase II trial
Relinde I. Y. Lieverse et al.
BMC CANCER (2020)
Camidanlumab tesirine, an antibody-drug conjugate, in relapsed/refractory CD25-positive acute myeloid leukemia or acute lymphoblastic leukemia: A phase I study
Aaron D. Goldberg et al.
LEUKEMIA RESEARCH (2020)
TransConTM IL-2 β/γ: a novel long-acting prodrug of receptor-biased IL-2 designed for improved pharmocokinetics and optimal activation of T cells for the treatment of cancer
David Brian Rosen et al.
CANCER RESEARCH (2020)
In vivo efficacy of bempegaldesleukin, immune checkpoint inhibition, and targeted radionuclide therapy in immunocompetent murine model of head and neck cancer
Gustavo A. Sosa et al.
CANCER RESEARCH (2020)
Engineered variants of Neo-2/15 potently expand CAR-T cells and promote antitumor activity in lymphoma and solid tumor mouse models
Isabel Leung et al.
CANCER RESEARCH (2020)
Combination of bempegaldesleukin and anti-CTLA-4 prevents metastatic dissemination after primary surgery or radiation therapy in a preclinical model of non-small cell lung cancer
Ryan J. Brown et al.
CANCER RESEARCH (2020)
Bempegaldesleukin (NKTR-214), a CD122 preferential IL-2 pathway agonist, augments the in situ vaccine response to radiation of an extracranial tumor in a murine melanoma model, conferring response at non-radiated tumor sites in the brain
Paul A. Clark et al.
CANCER RESEARCH (2020)
NKTR-358, A NOVEL IL-2 CONJUGATE, STIMULATES HIGH LEVELS OF REGULATORY T CELLS IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS
S. Siddhanti et al.
ANNALS OF THE RHEUMATIC DISEASES (2020)
NKTR-214+nivolumab in first-line advanced/metastatic urothelial carcinoma (mUC): Updated results from PIVOT-02.
Arlene O. Siefker-Radtke et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Safety and efficacy of adoptive cell transfer using autologous tumor infiltrating lymphocytes (LN-145) for treatment of recurrent, metastatic, or persistent cervical carcinoma.
Amir A. Jazaeri et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
A First-in-Human Study and Biomarker Analysis of NKTR-214, a Novel 1L2Rβγ-Biased Cytokine, in Patients with Advanced or Metastatic Solid Tumors
Salah-Eddine Bentebibel et al.
CANCER DISCOVERY (2019)
ANALYSIS OF CLINICAL DETERMINANTS DRIVING SAFETY AND EFFICACY OF CAMIDANLUMAB TESIRINE (ADCT-301, CAMI) IN RELAPSED/REFRACTORY (R/R) CLASSICAL HODGKIN LYMPHOMA (CHL)
G. Collins et al.
HEMATOLOGICAL ONCOLOGY (2019)
New therapeutic strategies based on IL-2 to modulate Treg cells for autoimmune diseases
Le Xu et al.
INTERNATIONAL IMMUNOPHARMACOLOGY (2019)
Neo-DREAM study investigating Daromun for the treatment of clinical stage IIIB/C melanoma
John T. Miura et al.
FUTURE ONCOLOGY (2019)
Immunological and clinical effects of low-dose interleukin-2 across 11 autoimmune diseases in a single, open clinical trial
Michelle Rosenzwajg et al.
ANNALS OF THE RHEUMATIC DISEASES (2019)
APhase II Study of Tumor-infiltrating Lymphocyte Therapy for Human Papillomavirus-associated Epithelial Cancers
Sanja Stevanovic et al.
CLINICAL CANCER RESEARCH (2019)
De novo design of potent and selective mimics of IL-2 and IL-15
Daniel-Adriano Silva et al.
NATURE (2019)
THOR-707, a novel not-alpha IL-2, elicits durable pharmacodynamic responses in nonhuman primates and efficacy as single agent and in combination with anti PD-1 in multiple syngeneic mouse models
Ingrid B. Joseph et al.
CANCER RESEARCH (2019)
Fine tuning subsets of CD4(+) T cells by low-dosage of IL-2 and a new therapeutic strategy for autoimmune diseases
Zhen Zhao et al.
INTERNATIONAL IMMUNOPHARMACOLOGY (2018)
Biology of IL-2 and its therapeutic modulation: Mechanisms and strategies
Suman Mitra et al.
JOURNAL OF LEUKOCYTE BIOLOGY (2018)
A human anti-IL-2 antibody that potentiates regulatory T cells by a structure-based mechanism
Eleonora Trotta et al.
NATURE MEDICINE (2018)
Selective targeting of engineered T cells using orthogonal IL-2 cytokine-receptor complexes
Jonathan T. Sockolosky et al.
SCIENCE (2018)
89Zr-labeled CEA-targeted IL-2 variant immunocytokine in patients with solid tumors: CEA-mediated tumor accumulation and role of IL-2 receptor-binding
Emilie M.J. van Brummelen et al.
Oncotarget (2018)
Pilot trial of the hu14.18-IL2 immunocytokine in patients with completely resectable recurrent stage III or stage IV melanoma
Mark R. Albertini et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2018)
Safety, PK/PD, and anti-tumor activity of RO6874281, an engineered variant of interleukin-2 (IL-2v) targeted to tumor-associated fibroblasts via binding to fibroblast activation protein (FAP).
Morten Mau Soerensen et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
NKTR-214 (CD122-biased agonist) plus nivolumab in patients with advanced solid tumors: Preliminary phase 1/2 results of PIVOT.
Adi Diab et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Engineering a Single-Agent Cytokine/Antibody Fusion That Selectively Expands Regulatory T Cells for Autoimmune Disease Therapy
Jamie B. Spangler et al.
JOURNAL OF IMMUNOLOGY (2018)
A long-lived IL-2 mutein that selectively activates and expands regulatory T cells as a therapy for autoimmune disease
Laurence B. Peterson et al.
JOURNAL OF AUTOIMMUNITY (2018)
Adct-301 (Camidanlumab Tesirine), a Novel Pyrrolobenzodiaze-Based CD25-Targeting Antibody Drug Conjugate, in a Phase 1 Study of Replased/Refractory Non-Hodgkin Lymphoma Shows Activity in T-Cell Lymphoma
Graham P. Collins et al.
BLOOD (2018)
Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial
Arjun V. Balar et al.
LANCET (2017)
Relationships between lymphocyte counts and treatment-related toxicities and clinical responses in patients with solid tumors treated with PD-1 checkpoint inhibitors
Adam Diehl et al.
ONCOTARGET (2017)
Cergutuzumab amunaleukin (CEA-IL2v), a CEA- targeted IL-2 variant- based immunocytokine for combination cancer immunotherapy: Overcoming limitations of aldesleukin and conventional IL-2-based immunocytokines
Christian Klein et al.
ONCOIMMUNOLOGY (2017)
Modeling the receptor pharmacology, pharmacokinetics, and pharmacodynamics of NKTR-214, a kinetically-controlled interleukin-2 (IL2) receptor agonist for cancer immunotherapy
Deborah Charych et al.
PLOS ONE (2017)
Intralesional treatment of metastatic melanoma: a review of therapeutic options
Benjamin Weide et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2017)
Low-dose interleukin-2 selectively corrects regulatory T cell defects in patients with systemic lupus erythematosus
Caroline von Spee-Mayer et al.
ANNALS OF THE RHEUMATIC DISEASES (2016)
NKTR-214, an Engineered Cytokine with Biased IL2 Receptor Binding, Increased Tumor Exposure, and Marked Efficacy in Mouse Tumor Models
Deborah H. Charych et al.
CLINICAL CANCER RESEARCH (2016)
Programmed Death-Ligand 1 Expression and Response to the Anti-Programmed Death 1 Antibody Pembrolizumab in Melanoma
Adil I. Daud et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Low-dose interleukin-2 treatment selectively modulates CD4+ T cell subsets in patients with systemic lupus erythematosus
Jing He et al.
NATURE MEDICINE (2016)
Intralesional administration of L19-IL2/L19-TNF in stage III or stage IVM1a melanoma patients: results of a phase II study
Riccardo Danielli et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2015)
Selective Treg reconstitution during lymphopenia normalizes DC costimulation and prevents graft-versus-host disease
Holly A. Bolton et al.
JOURNAL OF CLINICAL INVESTIGATION (2015)
Adoptive cell transfer as personalized immunotherapy for human cancer
Steven A. Rosenberg et al.
SCIENCE (2015)
interleukin-2: Biology, Design and Application
Natalia Arenas-Ramirez et al.
TRENDS IN IMMUNOLOGY (2015)
CEA-targeted engineered IL2: Clinical confirmation of tumor targeting and evidence of intra-tumoral immune activation.
Jan H. M. Schellens et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
The promise of low-dose interleukin-2 therapy for autoimmune and inflammatory diseases
David Klatzmann et al.
NATURE REVIEWS IMMUNOLOGY (2015)
Control of the Inheritance of Regulatory T Cell Identity by a cis Element in the Foxp3 Locus
Yongqiang Feng et al.
CELL (2014)
Intralesional Treatment of Stage III Metastatic Melanoma Patients with L19-IL2 Results in Sustained Clinical and Systemic Immunologic Responses
Benjamin Weide et al.
CANCER IMMUNOLOGY RESEARCH (2014)
High dose interleukin-2 (Aldesleukin) - expert consensus on best management practices-2014
Janice P. Dutcher et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2014)
The Immunocytokine L19-IL2 Eradicates Cancer When Used in Combination with CTLA-4 Blockade or with L19-TNF
Kathrin Schwager et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2013)
T-cell activation by treatment of cancer patients with EMD 521873 (Selectikine), an IL-2/anti-DNA fusion protein
Julien Laurent et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2013)
Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomised, double-blind, placebo-controlled trial
Ralf Gold et al.
LANCET (2013)
Low-dose interleukin 2 in patients with type 1 diabetes: a phase 1/2 randomised, double-blind, placebo-controlled trial
Agnes Hartemann et al.
LANCET DIABETES & ENDOCRINOLOGY (2013)
Rapamycin/IL-2 Combination Therapy in Patients With Type 1 Diabetes Augments Tregs Yet Transiently Impairs β-cell Function
S. Alice Long et al.
DIABETES (2012)
The tumor microenvironment at a glance
Frances R. Balkwill et al.
JOURNAL OF CELL SCIENCE (2012)
The immune contexture in human tumours: impact on clinical outcome
Wolf Herman Fridman et al.
NATURE REVIEWS CANCER (2012)
Durable Complete Responses in Heavily Pretreated Patients with Metastatic Melanoma Using T-Cell Transfer Immunotherapy
Steven A. Rosenberg et al.
CLINICAL CANCER RESEARCH (2011)
Interleukin-2 and Regulatory T Cells in Graft-versus-Host Disease
John Koreth et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Antitumor Activity of Hu14.18-IL2 in Patients With Relapsed/Refractory Neuroblastoma: A Children's Oncology Group (COG) Phase II Study
Suzanne Shusterman et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Anti-GD2 Antibody with GM-CSF, Interleukin-2, and Isotretinoin for Neuroblastoma.
Alice L. Yu et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
IL-2/anti-IL-2 antibody complexes show strong biological activity by avoiding interaction with IL-2 receptor α subunit CD25
Sven Letourneau et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Central role of defective interleukin-2 production in the triggering of islet autoimmune destruction
Qizhi Tang et al.
IMMUNITY (2008)
IL-2 regulates FOXP3 expression in human CD4+CD25+ regulatory T cells through a STAT-dependent mechanism and induces the expansion of these cells in vivo
Emmanuel Zorn et al.
BLOOD (2006)
Selective stimulation of T cell subsets with antibody-cytokine immune complexes
O Boyman et al.
SCIENCE (2006)
Structure of the quaternary complex of interleukin-2 with its α, β, and γc receptors
XQ Wang et al.
SCIENCE (2005)
Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer
JC Yang et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Control of regulatory T cell development by the transcription factor Foxp3
S Hori et al.
SCIENCE (2003)
Enhancement of the antitumor properties of interleukin-2 by its targeted delivery to the tumor blood vessel extracellular matrix
B Carnemolla et al.
BLOOD (2002)
JM2, encoding a fork head-related protein, is mutated in X-linked autoimmunity-allergic disregulation syndrome
TA Chatila et al.
JOURNAL OF CLINICAL INVESTIGATION (2000)
分享论文
